Proteonomix Bets On Dubai For Stem-cell Products
This article was originally published in PharmAsia News
Executive Summary
New Jersey-based biotech Proteonomix is betting big on emerging markets as the next frontier for its cell technology products; the company is about to commence operation of its Dubai joint venture XGen Medical as a launch pad for the region
You may also be interested in...
Middle East And North African Countries Represent New Growth Opportunities For Global Pharma Industry
After China and India, the Middle East and North African (MENA) regions could present another fast-growing opportunity for the global pharmaceutical industry. A recent launch of the first MENA-focused health fund by TVM Capital highlights the promise
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).